A spokesperson for the World Health Organization (WHO) told Sputnik that its Global Advisory Committee on Vaccine Safety (GACVS) was carefully assessing the reports on risks related to the use of the AstraZeneca vaccine against COVID-19.
A number of European states have suspended vaccination with the AstraZeneca drug as a precaution after reports on severe side-effects, including blood clots, that were allegedly triggered by the vaccine, Sputnik reported.
The European Medicines Agency said there was currently no indication that the reported negative effects had been caused by the vaccination.
"The GACVS is carefully assessing the current reports on the AstraZeneca vaccine. As soon as WHO has gained a full understanding of these events, the findings and any changes to current recommendations will be immediately communicated to the public," the spokesperson said on late Thursday as quoted by Sputnik.
The WHO representative stressed that the global health body was aware of some EU countries' decisions to suspend the use of the AstraZeneca vaccine.
"The information available so far indicates that the number of thromboembolic events in vaccinated people is no higher than that seen in the general population. The Committee further noted that the vaccine can continue to be administered while the investigation of cases of thromboembolic events is ongoing," the spokesperson added.
The World Health Organization declared the COVID-19 outbreak a pandemic on March 11, 2020. To date, more than 118.34 million people have been infected with the coronavirus worldwide, with over 2.62 million fatalities, according to Johns Hopkins University.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)